These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 20887378

  • 1. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S, Herbers U, Luedde T, Trautwein C, Tacke F.
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [Abstract] [Full Text] [Related]

  • 2. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y, Curtis M, Borroto-Esoda K.
    Antivir Chem Chemother; 2011 Aug 23; 22(1):13-22. PubMed ID: 21860069
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U, Amini-Bavil-Olyaee S, Mueller A, Luedde T, Trautwein C, Tacke F.
    J Viral Hepat; 2013 Feb 23; 20(2):141-8. PubMed ID: 23301549
    [Abstract] [Full Text] [Related]

  • 4. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F.
    Hepatology; 2009 Apr 23; 49(4):1158-65. PubMed ID: 19263474
    [Abstract] [Full Text] [Related]

  • 5. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C.
    J Virol; 2004 Aug 23; 78(16):8524-35. PubMed ID: 15280461
    [Abstract] [Full Text] [Related]

  • 6. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S, Desmond P, Locarnini SA.
    Hepatology; 2003 Jan 23; 37(1):27-35. PubMed ID: 12500185
    [Abstract] [Full Text] [Related]

  • 7. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M, Hülagü S, Akhan SC, Sentürk O, Meriç M, Cekmen M.
    Mikrobiyol Bul; 2009 Jul 23; 43(3):425-32. PubMed ID: 19795617
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun 23; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 9. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, Trautwein C, Tacke F.
    J Hepatol; 2009 Oct 23; 51(4):647-54. PubMed ID: 19586679
    [Abstract] [Full Text] [Related]

  • 10. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F.
    Eur J Gastroenterol Hepatol; 2014 Feb 23; 26(2):146-54. PubMed ID: 24025974
    [Abstract] [Full Text] [Related]

  • 11. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA.
    Eur J Gastroenterol Hepatol; 2008 Aug 23; 20(8):773-7. PubMed ID: 18617782
    [Abstract] [Full Text] [Related]

  • 12. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY.
    Antivir Ther; 2009 Aug 23; 14(7):985-93. PubMed ID: 19918102
    [Abstract] [Full Text] [Related]

  • 13. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
    Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F.
    J Virol; 2010 Jan 23; 84(2):1026-33. PubMed ID: 19889778
    [Abstract] [Full Text] [Related]

  • 14. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 15. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA.
    J Viral Hepat; 2005 Jul 15; 12(4):364-72. PubMed ID: 15985006
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr 15; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O.
    Scand J Gastroenterol; 2011 Sep 15; 46(9):1111-7. PubMed ID: 21623676
    [Abstract] [Full Text] [Related]

  • 19. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F.
    J Hepatol; 2007 Mar 15; 46(3):531-8. PubMed ID: 17239478
    [Abstract] [Full Text] [Related]

  • 20. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL, VIRGIL Surveillance Study Group.
    J Hepatol; 2010 Apr 15; 52(4):493-500. PubMed ID: 20185191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.